Day: February 14, 2024

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, Feb. 14, 2024 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (TSX: MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced that senior management will host a conference call on Friday, March 15, 2024 at 8:30 a.m. ET to discuss the REIT’s fourth quarter 2023 results. Fourth Quarter 2023 Results Conference Call and WebcastDATE: Friday, March 15, 2024TIME: 8:30 a.m. ETINSTANT JOIN BY PHONE: https://register.vevent.com/register/BIa559b131ef4b452390f2055469abdc0b (Click the URL to join the conference call by phone)Pre-registration is recommended. Upon registration, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. Please ensure you...

Company positioned at forefront of $208 billion global AI in healthcare market by 2030 PLEASANTON, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) — Healthcare Triangle Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a frontrunner in healthcare technology, announces a groundbreaking move with the launch of a new SaaS solutions designed to spearhead digital transformation and AI integration in the healthcare sector. This strategic announcement positions Healthcare Triangle at the forefront of driving innovation, aiming to revolutionize patient care, diagnostics, and treatment outcomes on a global scale. The announcement also unveils the Company’s initiative to forge partnerships with prominent AI technology providers, healthcare, pharmaceutical, and research institutions. These collaborations aim to amplify the reach...

RIDGEFIELD, Conn., Feb. 14, 2024 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its fourth quarter ended December 29, 2023. The fiscal quarter ended December 29, 2023 consisted of 13 weeks as compared to the fiscal quarter ended December 30, 2022, which consisted of 14 weeks. Financial highlights for the fourth quarter of 2023:Net sales increased 20.1% to $950.5 million for the fourth quarter of 2023 from $791.3 million for the fourth quarter of 2022. On a pro-rated basis, comparing 13-week to 13-week basis, net sales increased 29.3%. GAAP net income was $16.0 million, or $0.38 per diluted share, for the fourth quarter of 2023 compared to $1.2 million,...

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that CVW CleanTech Inc. (“CVW CleanTech” or the “Company”) (TSX-V: CVW; OTCQX: CVWFF) has qualified to trade on the OTCQX® Best Market. CVW CleanTech upgraded to OTCQX from the Pink® market. CVW CleanTech is the owner of a ready-to-deploy technology able to recover valuable commodities, including critical minerals and hydrocarbons, from froth treatment tailings generated by oil sands mining operations while abating approximately 90% of the methane emitted from an oil sands mining site. CVW CleanTech Inc. begins trading today on OTCQX under the symbol “CVWFF.” U.S. investors can find current financial and other relevant disclosures, and Real-Time Level...

TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular...

LATHAM, N.Y., Feb. 14, 2024 (GLOBE NEWSWIRE) — In a strategic move to enhance its financial performance and ensure long-term value creation in a competitive market, Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, today announced a comprehensive initiative designed to significantly reduce its annual operational expenses by more than $75 million. This ambitious plan will be executed with an expected one-time implementation cost of $15 million, underscoring the Company’s commitment to operational excellence and fiscal responsibility. The initiative encompasses a broad range of measures, including operational consolidation, strategic workforce adjustments, and various other cost-saving actions. These measures are aimed at increasing efficiency, improving scalability,...

Miami, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced it will release financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. Management will host a webcast and conference call the following day on Friday, March 1, 2024 at 8:30 a.m. Eastern time to review the Company’s results. Webcast and Conference Call The conference call will be broadcast live over the Internet. Additionally, a slide presentation will accompany the conference call. To listen to the call and view the slides, please visit the Investors section of Tecnoglass’ website at www.tecnoglass.com....

The eastern portion of the Rosita Property is 3km directly west of Filo Mining’s Filo del Sol Project and Sobek North is 3km southwest of NGEx´s Lunahuasi discovery The Rosita property hosts compelling structural lineaments, abundant geophysical anomalies and a very prospective geological environment Rosita exploration program to commence immediately to identify and refine targets for drilling Sobek Project doubled in size to 22,640 hectares Briefing Webinar to be scheduledVANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) —  Mirasol Resources Ltd. (TSX-V: MRZ) (OTC: MRZLF) (the “Company” or “Mirasol”) is pleased to announce the signing of a landmark option agreement (the “Agreement”) with Sociedad Química y Minera de Chile SA (“SQM”) doubling the size of the flagship Sobek Copper-Gold Project (“Sobek” or “the Project”)...

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway Through Late Third Quarter 2024 and Beyond Expected Timing of Unblinded Interim Analysis; Potential Additional $19 Million if Warrants are Exercised to Fund PolyPid to the Start of a Planned New Drug Application Submission for D-PLEX100  Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) —...

COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 COAST and ShORe top-line results expected by mid-2025 MELBOURNE, Australia, Feb. 14, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration (wet AMD). The sozinibercept clinical program...